세계의 결합 백신 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 브랜드별, 질환별, 병원균별, 환자별, 지역별, 부문별 예측(2024-2030년)

Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,272,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,662,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,443,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

결합 백신 시장 규모·동향

결합 백신 세계 시장 규모는 2023년에 190억 1,000만 달러로 추정되며, 2024-2030년에 걸쳐 CAGR 9.60%를 나타낼 것으로 예측됩니다. 세계의 감염증 이환율의 상승이 결합 백신 시장 성장의 큰 요인이 되고 있습니다. 결합 백신은 인플루엔자 균 B형(Hib), 폐렴구균 감염, 수막염균 감염 등과 같은 심각한 박테리아 질환을 예방하는 데 도움이 됩니다. CDC에 따르면, 폐렴구균, 특히 폐렴구균은 미국에서 박테리아성 수막염의 중요한 원인이며, 이 박테리아가 초래하는 건강에 중대한 부담이 부각되었습니다. 감염이 공중 보건을 위협하는 동안 효과적인 백신 접종 전략의 필요성이 높아지고 결합 백신 수요를 견인하고 있습니다.

결합 백신 시장을 견인하는 또 다른 중요한 요소는 새로운 결합 백신 제품에 대한 규제 당국의 승인이 증가하고 있다는 것입니다. 승인 건수 증가는 시장을 확대하고 산업 내 기술 혁신을 촉진합니다. 기업은 암메트 메디컬 니즈에 대응하고 신흥 감염증을 대상으로 하는 신규 결합 백신의 개발을 장려하고 있습니다. 예를 들어, 2024년 6월 미국 FDA는 침습성 폐렴구균 감염과 폐렴구균 감염을 예방하기 위해 성인용 폐렴구균 21가 결합 백신인 CAPVAXIVE를 승인했습니다. 이 승인은 폐렴 구균 감염과의 싸움에서 중요한 일리즈카입니다. 폐렴구균 감염은 심지어 노인과 특정 건강 문제가 있는 사람과 같은 고위험 그룹 사이에서 심각한 건강 문제를 일으키고 심지어 죽음에 이르기도 합니다.

세계 각국의 정부 활동과 예방접종 프로그램은 결합 백신 시장의 성장에 큰 영향을 미치고 있습니다. 예를 들어, WHO는 어린 시절 예방접종 프로그램에 폐렴구균 결합 백신(PCV)을 포함할 것을 세계적으로 권장합니다. 특히 5세 이하 아동 사망률이 출생 1,000명당 50명을 넘는 등 소아 사망률이 높은 국가는 이러한 다성분 PCV의 도입을 우선해야 합니다.

개인과 의료 종사자 사이에서 예방 의료 실천이 중시되고 감염에 대한 장기적인 방어를 제공하는 백신 수요가 높아지고 있습니다. 면역 반응을 향상시키는 능력을 가진 혼합 백신은이 예방 의료 접근법에 적합합니다.

혼합 백신 세계 시장 보고서 세분화

이 보고서는 2018-2030년에 걸쳐 수익 성장을 세계, 지역 및 국가 수준에서 예측하고 각 하위 부문에 대한 최신 업계 동향 분석을 제공합니다. 이 연구의 목적을 위해 Grand View Research, Inc.는 제품, 브랜드, 질병, 병원균, 환자 및 지역을 기준으로 세계 결합 백신 시장 보고서를 세분화합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 결합 백신 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련/보조적인 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 결합 백신 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 결합 백신 시장 : 제품, 추정·동향 분석

• 제품 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 제품별 세계의 결합 백신 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제5장 결합 백신 시장 : 브랜드, 추정·동향 분석

• 브랜드 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 브랜드별 세계의 결합 백신 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제6장 결합 백신 시장 : 질환, 추정·동향 분석

• 질병 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 질병별 세계의 결합 백신 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제7장 결합 백신 시장 : 병원균, 추정·동향 분석

• 병원균 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 병원균별 세계의 결합 백신 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제8장 결합 백신 시장 : 환자, 추정·동향 분석

• 환자 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 환자별 세계의 결합 백신 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석

제9장 결합 백신 시장 :지역, 추정·동향 분석

• 지역별 시장 점유율 분석, 2023년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2023년
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E. Ltd.
  • Bio-Med
  • CSL Limited
  • GSK plc
  • GSPBL
  • Merck &Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Taj Pharmaceuticals Ltd.

JHS

영문 목차

영문목차

Conjugate Vaccine Market Size & Trends

The global conjugate vaccine market size was estimated at USD 19.01 billion in 2023 and is expected to grow at a CAGR of 9.60% from 2024 to 2030. The rising incidence of infectious diseases globally is a significant driver for the growth of the conjugate vaccines market. Conjugate vaccines help protect against several serious bacterial diseases, including Haemophilus influenzae disease b (Hib, Pneumococcal infections, and Meningococcal infections. According to the CDC, pneumococci, specifically Streptococcus pneumonia bacteria, are a significant cause of bacterial meningitis in the U.S. highlighted the significant health burden posed by this bacterium. As infectious diseases threaten public health, there is a growing need for effective vaccination strategies, driving the demand for conjugate vaccines.

Another crucial factor driving the conjugate vaccines market is the rising regulatory approvals for new conjugate vaccine products. The increasing number of regulatory approvals expands the market and drives innovation within the industry. Companies are encouraged to develop novel conjugate vaccines to address unmet medical needs and target emerging infectious diseases. For Instance, in June 2024, the U.S. FDA approved CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine for adults, to prevent invasive and pneumococcal disease. This approval marks a significant milestone in the fight against pneumococcal infections, which can lead to serious health issues and even death, especially among high-risk groups such as the elderly and those with specific pre-existing health problems.

Governmental initiatives and immunization programs worldwide have significantly influenced the growth of the conjugate vaccines market. For Instance, the WHO recommended including Pneumococcal Conjugate Vaccines (PCVs) in childhood immunization programs globally. Specifically, countries with high rates of childhood mortality, such as an under-5 mortality rate exceeding 50 deaths per 1000 births, should prioritize the introduction of these multicomponent PCVs.

Increasing emphasis on preventive healthcare practices among individuals and healthcare providers drives the demand for vaccines that offer long-term protection against infectious diseases. Conjugate vaccines, with their ability to enhance immune responses, align well with this preventive healthcare approach.

Global Conjugate Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global conjugate vaccine market report on the basis of product, brand, disease, pathogen, patient, and region

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Monovalent Conjugate Vaccine
• Multivalent Conjugate Vaccine
• Brand Outlook (Revenue, USD Million, 2018 - 2030)
• Prevnar
• Synflorix
• PedvaxHIB
• Hiberix
• ACT-HIB
• Pentacel
• Menveo
• Menactra
• MenQuadfi
• VAXNEUVANCE
• CAPVAXIVE
• Others
• Disease Outlook (Revenue, USD Million, 2018 - 2030)
• Pneumococcal
• Influenza
• DTP
• Meningococcal
• Typhoid
• Pathogen Outlook (Revenue, USD Million, 2018 - 2030)
• Bacterial
• Viral
• Combination
• Patient Outlook (Revenue, USD Million, 2018 - 2030)
• Pediatric
• Adults
• Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Brand
  • 1.2.3. Disease
  • 1.2.4. Pathogen
  • 1.2.5. Patient
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Brand outlook
  • 2.2.3. Disease outlook
  • 2.2.4. Pathogen outlook
  • 2.2.5. Patient outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Conjugate Vaccines Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of infectious disease
    • 3.2.1.2. Regulatory Approvals
    • 3.2.1.3. Government Initiatives and Immunization Programs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Conjugate Vaccine
    • 3.2.2.2. Stringent Regulatory Requirements
• 3.3. Conjugate Vaccines Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Conjugate Vaccines Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Conjugate Vaccines Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Monovalent Conjugate Vaccine
    • 4.4.1.1. Monovalent conjugate vaccine market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Multivalent Conjugate Vaccine

4.4.1.2.1. Multivalent conjugate vaccine market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Conjugate Vaccines Market: Brand Estimates & Trend Analysis

• 5.1. Brand Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Conjugate Vaccines Market by Brand Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Prevnar
    • 5.4.1.1. Prevnar market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Synflorix
    • 5.4.2.1. Synflorix market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. PedvaxHIB
    • 5.4.3.1. PedvaxHIB market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Hiberix
    • 5.4.4.1. Hiberix market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. ACT-HIB
    • 5.4.5.1. ACT-HIB market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Pentacel
    • 5.4.6.1. Pentacel market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Menveo
    • 5.4.7.1. Menveo market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Menactra
    • 5.4.8.1. Menactra market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.9. MenQuadfi
    • 5.4.9.1. MenQuadfi market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.10. VAXNEUVANCE
    • 5.4.10.1. VAXNEUVANCE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.11. CAPVAXIVE
    • 5.4.11.1. CAPVAXIVE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.12. Others
    • 5.4.12.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Conjugate Vaccines Market: Disease Estimates & Trend Analysis

• 6.1. Disease Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Conjugate Vaccines Market by Disease Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Pneumococcal
    • 6.4.1.1. Pneumococcal market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Influenza
    • 6.4.2.1. Influenza market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. DTP
    • 6.4.3.1. DTP market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Meningococcal
    • 6.4.4.1. Meningococcal market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Typhoid
    • 6.4.5.1. Typhoid market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Conjugate Vaccines Market: Pathogen Estimates & Trend Analysis

• 7.1. Pathogen Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Conjugate Vaccines Market by Pathogen Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Bacterial
    • 7.4.1.1. Bacterial Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Viral
    • 7.4.2.1. Viral market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Combination
    • 7.4.3.1. Combination market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Conjugate Vaccines Market: Patient Estimates & Trend Analysis

• 8.1. Patient Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Conjugate Vaccines Market by Patient Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Pediatric
    • 8.4.1.1. Pediatric Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Adults
    • 8.4.2.1. Adults market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Conjugate Vaccines Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. North America
  • 9.5.2. U.S.
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Canada
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Mexico
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. Europe
  • 9.6.2. UK
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ Reimbursement
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Germany
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ Reimbursement
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. France
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ Reimbursement
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Italy
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ Reimbursement
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Spain
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Denmark
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ Reimbursement
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Sweden
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.9. Norway
    • 9.6.9.1. Key country dynamics
    • 9.6.9.2. Regulatory framework
    • 9.6.9.3. Competitive scenario
    • 9.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Asia Pacific
  • 9.7.2. Japan
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ Reimbursement
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. China
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ Reimbursement
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. India
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ Reimbursement
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. Australia
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ Reimbursement
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. South Korea
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ Reimbursement
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.7. Thailand
    • 9.7.7.1. Key country dynamics
    • 9.7.7.2. Regulatory framework/ Reimbursement
    • 9.7.7.3. Competitive scenario
    • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Latin America
  • 9.8.2. Brazil
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/ Reimbursement
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. MEA
  • 9.9.2. South Africa
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ Reimbursement
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. Saudi Arabia
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ Reimbursement
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. UAE
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ Reimbursement
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.5. Kuwait
    • 9.9.5.1. Key country dynamics
    • 9.9.5.2. Regulatory framework
    • 9.9.5.3. Competitive scenario
    • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. Bavarian Nordic
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Others benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Bharat Biotech
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Others benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Biological E. Ltd.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Others benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Bio-Med
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Others benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. CSL Limited
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Others benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. GSK plc
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Others benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. GSPBL
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Others benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Merck & Co., Inc.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Others benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Novartis AG
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Others benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Pfizer, Inc.
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Others benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Sanofi
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Others benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. Serum Institute of India Pvt. Ltd.
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Others benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. Taj Pharmaceuticals Ltd.
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Others benchmarking
    • 10.3.16.4. Strategic initiatives

관련자료